BiLirubin Decrease Under Phototherapy Exposure in the Preterm Newborn in Incubator
BiLirubin Decrease Under Phototherapy Exposure in the Preterm Newborn in Incubator
Phototherapy is routinely used in neonatal intensive care units for the treatment of
 jaundice. Guidelines focus mainly on bilirubin serum levels to start the phototherapy. Only
 few data are available about clinical management of phototherapy devices and subsequently the
 impact on bilirubin serum decrease. Especially there are no strong recommendations about
 phototherapy duration, irradiance measurements, incubator temperature and humidity settings.
 Various factors can influence irradiance and thus the preterm infant bilirubin serum
 decrease. This study aims at evaluating the impact of an educational program on the use and
 efficacy of phototherapy in a neonatal intensive care unit.
Only few data are available about clinical management of phototherapy devices for the
 treatment of jaundice in the preterm infant.

 This study is a prospective, monocentric, observational study. Preterm infant < 35 weeks of
 gestation with a jaundice requiring phototherapy according to NICE guidelines can be included
 for the duration of the phototherapy treatment.

 The decrease in bilirubin serum level before and after phototherapy treatment will be
 measured.

 This decrease in bilirubin serum level will be assessed for two consecutive periods before
 and after an educational program on jaundice management of the preterm infant.

 The investigators aim at demonstrating that an educational program could improve phototherapy
 management and result in a higher decrease in bilirubin serum during treatment of the preterm
 infant with jaundice.
Inclusion Criteria:

 -  preterm infant less than 35 weeks gestation

 -  preterm infant hospitalized in the neonatal intensive care unit of CHU Amiens-Picardie

 -  preterm infant placed in an incubator

 -  preterm infant with a jaundice requiring treatment according to NICE guidelines

 -  preterm infant with a no hemolytic disease

 -  preterm infant with informed written consent from the parents

 Exclusion Criteria:

 -  preterm infant more than 35 weeks of gestation

 -  preterm infant with hemolytic disease

 -  preterm infant with Jaundice related to a cholestasis

 -  Jaundice requiring exchange transfusion